PQRI Case Study (6): Packaging Line GMP Optimization - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

PQRI Case Study (6): Packaging Line GMP Optimization
The sixth in a series of eight case studies from the Product Quality Research Institute focuses on packaging line GMP optimization.

Pharmaceutical Technology
pp. 46-48

Packaging represents a critical manufacturing operation requiring strong GMPs and quality oversight to ensure sustained and robust compliance. Historically, inadequate packaging practices have been a meaningful ongoing contributor to product recall actions industry-wide. A strong understanding of the compliance risks associated with product packaging is a necessary and important component of a good quality system.

This case study on packaging line GMP optimization is the sixth of eight in a series put together by the Product Quality Research Institute Manufacturing Technical Committee (PQRI–MTC) risk-management working group. The series is meant to advance the understanding and application of the International Conference on Harmonization (ICH) Q9 Quality Risk Management guideline by providing actual examples of risk-management assessments used by the bio/pharmaceutical industry.

The introductory article and first case study, on defining design space, appeared in the July 2011 issue of Pharmaceutical Technology (1). Subsequent case studies in the series (8 in total) can be viewed online at http://PharmTech.com/PQRIstudies.

In this case study, the authoring firm has enjoyed satisfactory compliance performance across their international packaging operations. Nonetheless, recognizing the criticality that packaging plays in ongoing quality assurance, the firm engaged in a risk-assessment of a number of established packaging lines at several key packaging sites worldwide. The goal of the assessment was to further enhance the quality assurance of existing packaging operations and practices.

The risk question and risk-assessment method

The risk question developed for the subject case study is: What processes, procedures, and/or events during the packaging of a product create an unacceptable risk, real or perceived, to the quality of that product as received by our customers?

The project team assigned to this initiative sought to find a method that was inductive, systematic, and comprehensive, with the understanding that the risk factors for this application were generally well defined and quantitative. The risk tool selected to perform the analysis was: functional failures and effects analysis (FFEA). This tool represents a hybrid of failure modes and effects analysis, or FMEA, and uses a risk matrix instead of a risk priority number (RPN). FFEA is a systematic, function-based method for examining the effects of functional failures on system performance.

In this case study, a team of subject-matter experts conducted the analysis by identifying and assessing the effects on a system associated with individual functional failures. To apply risk-based, decision-making concepts to the FFEA, the team also identified the frequency of each functional failure and the severity of the potential effect (outcome) and compared each to predetermined risk-acceptance criteria. The team suggested corrective actions when required by the risk-acceptance criteria or when the team identified opportunities for improvement.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here